Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 68Lymphoma, Non-Hodgkin 53Lymphoma, Large B-Cell, Diffuse 47Hodgkin Disease 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 41Small Cell Lung Carcinoma 37Leukemia 37Burkitt Lymphoma 32Lymphoma, Mantle-Cell 29Lymphoma, Follicular 28Lung Neoplasms 20Carcinoma, Non-Small-Cell Lung 20Multiple Myeloma 19Congenital Abnormalities 18Lymphoma, Large-Cell, Immunoblastic 17Lymphoma, Large-Cell, Anaplastic 17Recurrence 15Lymphoma, B-Cell, Marginal Zone 15Lymphoma, B-Cell 15Leukemia, Lymphocytic, Chronic, B-Cell 15Neuroblastoma 13Neoplasms 13Myelodysplastic Syndromes 11Waldenstrom Macroglobulinemia 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, T-Cell 10Immunoblastic Lymphadenopathy 10Sarcoma 9Myeloproliferative Disorders 9

Interventions

olaparib 1cediranib 1bomedemstat 1atezolizumab 1Platinum 1Immunoglobulin G 1Etoposide 1Disulfides 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Extensive Stage Lung Small Cell Carcinoma × Etoposide × Clear all
NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡